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I. INTRODUCTION 
In the last decade the need to image the heart has 
led to the investigation of various ions that could serve 
as cardiac imaging agents in healthy and in non-functioning 
cardiac tissue and provide prognostic information allowing 
earlier medical or surgical intervention in patients with 
acute myocardial Infarction. 
These imaging agents have been found to function by 
mimicking the action of the normal in vivo cations (ie. K*). 
Thallium (to be discussed in greater detail later) has been 
shown to function as an excellent K+ analogue in many systems 
(1) and to serve as an excellent myocardial imaging agent 
for the relative quantitation of infarct size (2,3). Gustin 
(4) in 1975 felt that Cesium-129 was also an accurate myocar¬ 
dial imager for the localization and relative quantification 
of acute myocardial infarction. A future goal would 
be to accurately quantify infarct size using these tech¬ 
niques. To be able to use cardiac imaging in a quantitative 
manner, we must understand factors affecting the uptake of 
the Imaging agent thallium. 
It is well established that diuretic drugs effect ca¬ 
tionic balance in the renal tubule (5^6). Only a few studies 
have shown an extrarenal site of diuretic drug action. 
Sellers in 1975 (7) provided some of the earliest evidence 
for diuretics exerting a direct effect on the myocardium. 

He found that furosemide and ethacrynic acid individually 
increased the digitalis induced myocardial loss of potassium 
from the dog heart as measured by arterial-venous differences. 
In addition there is evidence that ethacrynic acid and triam¬ 
terene act on the erythrocyte Na+,K+-ATPase as well as the 
renal tubule cells. With these leads on the extrarenal sites 
of action of diuretics as well as with the many known changes 
in cationic balance caused by diuretics, we felt it was 
reasonable to study one of these diuretics in relation to the 
myocardium in more detail. 
It is the goal of this investigation to study the 
potent kaliuretic diuretic, furosemide, in an in vivo mammal¬ 
ian system, to see if its acute or chronic administration 
under an eukalemic or chronic hypokalemic environment, affects 
the myocardial tissue concentration and kinetics of 
thallium-201 under these various conditions. We anticipate that 
the information derived from this study may help to contri¬ 
bute to the understanding of the mechanisms of the interre¬ 
lationship between potassium dynamics, cationic enzyme systems, 
and furosemide; in addition, it may eventually 
contribute to the knowledge needed for accurately sizing 
myocardial infarcts with ^OLpi. 
-2- 
la 
II. IMAGING AGENTS - THALLIUM-201 
Thallium, a metallic element in group IIIA of the 
periodic table (2), has properties that closely resemble 
potassium in biologic systems, suggesting to Kawana that 
tracer quantities of 201 T1 may be used to image the 
myocardium(2). 
Available evidence suggests that the movement of 
thallous thallium and potassium in animals is related (1). 
Mullins and Moore (8) found that both the influx and efflux 
patterns of thallium were very similar to potassium when 
frog muscle was used as a test tissue. Gehring and Hammond 
in 1964 (9) presented evidence indicating that the mechanism 
associated with the active transport of potassium into rabbit 
erythrocytes also transported thallium. All the experiments 
suggested a great similarity in the ionic movements of thall¬ 
ium and potassium. By determining and comparing the disap¬ 
pearance of 20^T1 and from plasma and the uptake of these 
ions by tissues as a function of time, the degree to which 
these ions are interchangeable was characterized(1). The 
concentrations of 204ip]_ an£ 42^ qn heart, lung, muscle, 
intestine, skin, brain, liver and spleen as a function of 
time were similar. The high initial concentration of these 
ions in the heart and lung immediately following injection 
were related to blood flow (1). 201rp]_ concentrates in the 
myocardium in relation to the distribution of regional 
perfusion under normal flow, and partial and total occlusion 
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of the coronary artery(2). Thallium appears to concentrate 
in the myocardium to a greater degree than potassium and ru¬ 
bidium, 2.08 % dose compared to 1.25 % dose and 1.15 % dose 
respectively at 10 minutes, which is the time most commonly 
employed for imaging(2). 
Maximal myocardial and renal concentration occurs at 
10 minutes. The maximal total organ content of thallium in 
the myocardium is 3*7 % of the injected dose at 10 to 25 
minutes. The half life of 201f]_ j_n the myocardium is in two 
parts: 4.4 hours (78#) and 40 hours (22%). The half life 
of 201fp from the blood is less than one minute(lO). 
Gehring and Hammond(l) felt that since the concentra¬ 
tion of ^C^Tl j_n the heart and lung were consistently greater 
than that of these tissues probably had a slightly 
greater affinity for the 204^]^ and although the uptake of 
^O^Tl and by tissues may be related, there are sites with¬ 
in the cell having a greater affinity for thallium than for 
potassium(1). The kinetic analysis of simultaneous plasma 
decay data for 204^ and 42^ suggested that the uptake of 
these ions by tissues are similar. An analysis of the organs 
of the body suggested that handling of 204ff an(j 42^ by the 
kidney, testes and intestine was different(1). 
Since the uptake of potassium is in part dependent on 
an active trasport system and since the uptake of thallium 
and potassium by tissue compartments is related, thallium 
probably is also actively transported into cells. It has 
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been shown in rabbit erythrocytes that the movement of 
thallium into the cells results from the active transport of 
thallium by a mechanism responsible for the active transport 
of potassium(9). Evidence strongly suggested that Na+,K+ 
activated ATPase isan essential component of the active K 
transport mechanism(11). The finding that thallium can 
substitute for potassium in causing activation of this 
enzyme provided further evidence that the uptake of thallium 
by all cells in part occurs via the active transport system 
associated with the uptake of potassium(l). In addition, 
/ 
Britten and Blank in 1968 (12) found that thallium replaces 
potassium in activating the Na+,K+-sensitive ATPase of rabbit 
kidney with an affinity approximately ten times potassium for 
the potassium activating site. An additional property that 
thallium and potassium have in common is their limiting ionic 
conductances in water at 25°C (Tl+, 74.7 and K+, 73-54), 
indicating that the hydrated Tl+ is almost identical in size 
to the hydrated K+. It is undecided whether the substitution 
is by hydrated ions at the solvated site or by free ions inter¬ 
acting with an enzyme site. It has also been shown that 
thallium is handled like potassium by rat sartorius muscle 
and also that thallium behaves like potassium during electri¬ 
cal excitation of that tissue. These studies established 
that thallium is a substitute for potassium in vivo(12). 
Potassium-43 is not considered ideal for imaging because 
of its high photon energies (373 and 619 kev), short shelf 
-5- 
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life (t 1/2 = 22.4 hours), and high cost. Thallium-201, with 
all the evidence for its functioning as an excellent analog 
of potassium in vivo, on the other hand, is considered ideal 
to use as an imager since it emits relatively low energy 
gamma photons of 69-83 kev in 90% abundance plus gamma rays 
of 135 (2%) and 167 (8%) kev in 10% total abundance, giving 
lower total body radiation to the patient, has a half life 
of 73-5 hours, has a short time interval both between the 
injection and the optimal scintiscan (10-20 minutes) and 
between the onset of infarction and scintigraDhic results 
(few hours)(2,3,13)• Its low energy photon and X-ray emissions 
make the use of high resolution low energy collimators with 
either the rectilinear scanner or scintillation camera fea¬ 
sible to image the tracer while imaging K or Rb requires 
high energy low resolution collimators(14,15,16). Since 
the low energy X-ray emission from thallium-201 are more 
abundant and the resolution with the two high resolution 
scintillation camera systems is satisfactory with the narrow¬ 
er window, the X-ray is the optimal method of imaging thall¬ 
ium^). Imaging with thallium-201 after an acute myocardial 
infarct gives a dose of 3.8 rads per mCi to the kidneys of 
man. 12% of administered activity is excreted with the urine 
and 6% with the feces(3). 
During the acute phase of a myocardial infarction, both 
necrotic and ischemic tissue is demonstrated by thallium-201 
since this ion concentrates in the myocardium in relation to 
the distribution of regional myocardial flow. Subsequent 
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formation of collaterals in previously ischemic regions leads 
to recurrence of thallium-201 uptake. Defect size depends 
on the time of the scintigraphic study after the onset of the 
infarct and must be considered if quantification of infarct 
size by thallium-201 is to be attempted. Disadvantages of 
thallium-201 scintigraphy are that no exact differentiation 
can be made between acute infarction and ischemia and that 
thallium-201 cannot distinquish between old and new infarct¬ 
ion. Thallium-201 has the advantage of its use in early de¬ 
tection within 6 hours, and probably within minutes, after 
the onset of symptoms(17)• 
Thallium differs from potassium in that thallium is 




Furosemide is a weak anthranilic acid derivative 
producing dilatation of renal vasculature and an increased 
blood flow rate especially in the renal cortex and a decreased 
rate in the outer medulla(18,19,20). After oral intake the 
diuretic response occurs within an hour. Given intravenously 
it occurs within 2-10 minutes with peak electrolyte response 
in 30 minutes. After intravenous administration, some furo¬ 
semide is filtered at the glomerulus although more important 
is secretion by the proximal tubule, both of which give a 
combined excretion of two-thirds of the diuretic. The 
proximal tubule secretion is blocked by competitive inhibitors 
of proximal tubule organic acid transport. The remaining 
third is excreted in feces. Furosemide is bound to dog 
plasma protein 85-90/5(19). The highest concentration of 
unchanged drug following furosemide is found in kidney, 
liver, plasma and lung. Heart, muscle and fat show less 
radioactivity per gram of tissue than seen per ml of plasma. 
Furosemide appears in urine intact (96-99% of total urinary 
radioactivity) within the first 1/2 hour after intravenous 
administration. In a 24 hour collection period, 80% of 
urinary radioactivity excreted by dogs remained unchanged(19). 
(Mechanisms of action to be discussed in section IV). 
- 
IV. MECHANISMS OF POTENT DIURETICS WITH EMPHASIS ON 
FUROSEMIDE AND POTASSIUM EXCHANGE 
Many studies have shown that the active movements of 
Na+ and K+ are closely linked under most conditions, since 
+ 
inward K transport occurs only with an outward movement of 
Na ions. A membrane bound energy dependent ATPase (with a 
molecular weight between 300,000-400,000) is known to mediate 
the active movement of these cations through the plasma mem¬ 
brane of the renal tubular cell, red blood cell and myocardium 
and this enzyme is stimulated synergistically by internal 
Na+ ions and external K+ ions(11,20,21). Skou in 10^0 (22) 
first demonstrated that this Na+;K+-ATPase is inhibited by 
ouabain. 
It has been found that 3 Na ions bind on the inside 
and two K Ions bind on the outside of the red blood cell mem¬ 
brane Na ,K -ATPase ("pump") for each molecule of ATP 
hydrolyzed. This ATPase requires ATP hydrolysis at a rate 
dependent on external K*"and internal Na+ concentrations, and 
is specifically sensitive to inhibition by cardiac glycosides 
unlike other ATPases which do not depend on Na1” and K*~for 
their function and are probably associated with other cellular 
functions. Eoth Na ions inside and K ions outside are needed 
to stimulate the pump-enzyme because these Na" and lions' 
active transport in the red blood cell is coupled(21). 
Levels of activity of Na+,K+-ATPase in a given tissue 
correlates well with the rates of active cation transport 
and pumping rate in the same tissue. The specific activity 
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of this enzyme from red blood cells is only l/2000th of it 
in kidney preparation(21). The small distal tubular cell 
mass possesses an extremely high activity of Na+,K+-ATPase 
compared with other tubular structures as found by quantita¬ 
tive histochemical studies(20). The highest Na+,K+-ATPase 
activities were measured in the outer medulla largely made 
up of the thick ascending limbs of Henle's loop(23). 
Glycosides given intraarterially produce natriuresis 
and reduction in renal concentrating ability with an'inhibi- 
*4“ 
tion of Na ,K -ATPase activity in the cortex and medulla of 
infused kidney(23). The rate of binding of ouabain rather 
than its capacity for binding to outer red blood cell mem- 
branes Na ,K -ATPase (and to other systems where ouabain is 
effective in inhibiting this ATPase, ie. myocardium), is 
depressed proportionally by increasing the external K+ concen- 
tration(21,24,25). However, this increase in K concentration 
eventually alters neither the peak inotropic effects of 
digoxin nor the myocardial concentration of H-digoxin; it 
only slows the rates to its achievement(25). In addition, 
+■ 
K appears to decrease the rate of combination of ethacrynic 
acid with this transport system(26). There is much evidence 
that when the cell gets enough digoxin to inhibit the pump 
+ + 
completely, the permeation of Na and K through the membrane 
is not entirely accounted for by passive "leakages". 
Ethacrynic acid partially inhibits this remaining Na+ outflux 
and K influx In digoxin treated cells through a digoxin-insen- 
sitive pump (ATPase) called Pump II. This pump is not affected 
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by the external K concentration(27). The digoxin-sensitive 
pump (ATPase) which exchanges Na+ for K+ is called Pumn 1(28). 
The kinetic behavior of the active K influx in the 
presence of digoxin and ethacrynic acid is consistent with a 
model in which binding of K at one of the K-sensitive sites 
in the transport system reduces the affinity of the system 
for the ethacrynic acid and binding of a second ion further 
reduces the affinity(26). Another possibility is that digoxin 
does not compete for the K+ or Na+ sites on the ATPase but 
binds to an allosteric site on the cell membrane which leads 
to a conformational change on the ATPase enzyme which then 
inhibits its transport functions(29,30). 
Furosemide, as well as other potent diuretics, has 
been found to affect cationic movement in systems other than 
the renal tubule, such as the red blood cell, salivary duct 
epithelium and the myocardium(7,31,32). 
There are a number of different explanations existing, 
many of which are interrelated, about how furosemide causes 
natriuresis. Furosemide exerts its effect from the luminal 
surface of the tubule(33). Inhibition of ionic absorption 
from the ascending limb of the loop of Henle is one of the 
major effects of furosemide in the human kidney and this has the 
effect of reducing the diluting and concentrating ability of 
patients(18). Furosemide also leads to a metabolic alkalosis 
since more chloride is lost than bicarbonate, in addition to 
the increased loss of hydrogen and potassium(27). 
Furosemide affects several transport processes in the 
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kidney. It is known to cause increased urinary loss of 
sodium, chloride, calcium, and magnesium by the same ner 
cent as sodium and to a lesser extent potassium in man; 
these effects are independent of glomerular filtration rate(l8). 
On micro puncture and microperfusion studies on single 
nephron segment, Burg in 1973 (33) showed that in rabbit thick 
ascending limb of Henle’s loop that the active transport of 
chloride is the driving force for ionic movement and that 
sodium ions passively followed the chloride. Furosemide, at 
-5 -6 
a concentration of 10 or 10 M in luminal fluid ,inhibits 
this chloride transport process only in the thick ascending 
limb in vitro and not elsewhere in the tubule, with a decrease 
in net NaCl absorption and potential difference at the lumen 
-4 
from _5 to 0. Concentrations of furosemide as high as 10 M 
whether placed In the bath and/or the lumen had no definite 
effect on the proximal convoluted tubules or cortical collect¬ 
ing tubules(33). Natochin in 1976 (44) working with frog 
skin found that furosemide decreases chloride permeability 
rather than inhibiting the chloride pump as found by Burg(33)j 
then leading to the inability of the cells to reabsorb the 
sodium(34). 
Since the thick ascending limb is the major site of 
NaCl reabsorption in the distal nephron, inhibition of its 
function could lead to a greater diuresis than a comparative 
inhibition limited to the proximal tubule(33). 
Schmidt and Dubach in 1970 (20) reported that furose- 
+ + 




of Henle's loop and distal tubules of rat in the same areas 
+ + 
where the Na ,K ATPase is found to be most abundant and most 
likely mediates Na transport, and that it was unclear if 
any relation between this ATPase and the active chloride trans¬ 
port existed(20,33) . 
Most investigators believe in a direct influence of 
furosemide on cell metabolic pathways linked to cation trans¬ 
port by directly inhibiting renal oxidative metabolism(7,20,35,36). 
In vivo and in vitro studies revealed a depressed oxygen 
-4 
uptake in renal slices after 10 M furosemide to about the 
_ ^ 
same extent as 10 M ouabain, both being high doses. A 
competitive inhibition of energy production was noted(20). 
Manuel in 1976 (36) found that both ethacrynic acid and fur¬ 
osemide inhibited oxidative phosphorylation in the rat kidney 
in vitro by inhibiting electron transport through phosphory¬ 
lation site II. Biochemical bypass of site II significantly 
alleviated the respiratory inhibition by both agents. Both 
diuretics caused a reduction of flavoproteins and an oxidation 
of the cytochromes. 
Kessler in 1969 (37) demonstrated in dogs that furose¬ 
mide caused a natriureses of 30 to 407 of the filtered load 
of sodium. Cortical concentration of nucleotides were unaffected 
whereas in the medulla, ATP and ADP rose in a similar way as 
found after ouabain application. Thus furosemide appears 
either to stimulate ADP and ATP production or, more likely, 
to inhibit medullary ATP utilization. According to Kessler, 
reduction of the Na+,K+ATPase may explain these results with 
-13- 
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this ATPase also acting as the renal receptor for furosemide. 
In 1956, Glynn (38) demonstrated that the passive 
*4" *■{■ 
movements of Na and K ions deviated from the values expected 
of independent leaks of each cation down its own electrochem¬ 
ical gradient. This discrepancy has been generally attributed 
to exchange diffusion (which is an equal flux of a single ion 
species in both directions across the membrane mediated by 
the same carrier that cannot bring about a net ion transport) 
% 
and there is some evidence that at least part of the ouabain- 
insensitive Na+ movements in red cells results from this pro¬ 
cess (39) • 
A second possible explanation is that ouabain-insensi- 
+ 4- 
tive fluxes of Na and K are not independent but are coupled. 
Several findings suggest that Na+ and K+ may be cotransported 
into the red cell by the same mediated process. First, Na+ 
influx is stimulated by the presence of K+ ions in the medium 
and this increment in Na+ influx is prevented by furosemide. 
Similarly, the K+ influx, 20-25! of which persists in the 
presence of ouabain, is doubled or tripled when Na+ ions 
are added to the medium and this increment in K+ influx is 
abolished by furosemide. The synergism observed between the 
inward movement of Na+ and K+ in the presence of ouabain 
suggests that each ion facilitates the inward transport of 
the other. Moreover, the inhibition of the K+-stimulated 
+ . + + 
Na -influx as well as the Na -stimulated K -influx by furose¬ 
mide indicates that these mutually stimulated cation fluxes 
occur through the same pathway, which is sensitive to 
furosemide(23,32,39,^0). 

Since the magnitude of the furosemide sensitive influxes 
of Na+ and K+ are not significantly different (0.39 and 0.12 
ueq/ml cell/h respectively) the data are consistent with an 
inwardly directed cotransport mechanism, defined as a stoich¬ 
iometric coupling between the inward movement of Na+ and K+ 
and for which each ion is the preferred but not the obligatory 
substrate. K+ influx in the presence of ouabain does not 
increase in direct proportion to the external concentration 
of K+ but tends to reach a limiting value as the concentration 
is increased(4l). But in the presence of furosemide, the 
+ 
ouabain-insensitive K influx shows a linear dependence of 
external K+ concentration. Thus furosemide eliminates a com¬ 
ponent of K+ influx that shows the saturation kinetics 
typical of a facilitated diffusion process. Omission of Na 
from the medium likewise elimiates a saturable component of 
K+ influx and the magnitude of the Na+ sensitive component 
was nearly equal to the component inhibited by furosemide(4l,42) 
Wiley (32) feels that one implication of this linkage 
+ + 
observed between inward movement of Na and K is that a 
minimum of two transport sites are present on the outward¬ 
facing aspect of the furosemide-sensitive pathway. While these 
+ + 
two sites show specificity for Na and K , respectively, it 
is likely that the specificities are not absolute and that 
each ion is not an obligatory cosubstrate. Thus the furose- 
+ + 
mide-sensitive mechanism may transport not only Na -K pairs 
+ + + 
but also K -K pairs, if Na is unavailable for combination 




confined to inhibition of cation co-transport but furosemide 
also inhibits active cation fluxes by 10-15$ as measured either 
by active K influx or active Na efflux (32). 
Cotransport mechanisms are now recognized in a variety 
of tissues in which a coupled movement of Na+ ions together 
with amino acids or sugar can lead to net movement of these 
solutes. Such movements can occur even against a concentra¬ 
tion gradient and it seems likely that the energy for uphill 
solute movement is derived from the coupled movement 'of Na+ 
down its gradient (43). An analogous cotransport of Na+ 
plus K+ ions should likewise result in inward K+ movement 
against the concentration gradient of this ion. Thus, this 
study demonstrated that furosemide inhibited the ouabain- 
insensitive efflux of both Na+and K+ by an action that is not 
simply due to an inhibition of exchange diffusion (32). 
The clinical use of furosemide during an acute myocar¬ 
dial infarction with pulmonary congestion is well established 
in medical practice. In an acute myocardial infarction, the 
use of furosemide gives clinical relief of symptoms of pulmon¬ 
ary congestion frequently preceding any demonstrable diuretic 
effect, suggesting that extrarenal factors may also be Involved 
(44). These acute cardiovascular effects are due to changes 
in the effective circulating volume, electrolyte alterations, 
direct effects on the vascular beds and secondary reflex 
effects (34,45). After an intravenous dose of furosemide, 
venous capacitance rises, limb vascular resistance declines 
at 5 minutes, along with a decrease in left ventricular 
-16- 
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filling pressure from about 20 to 14 mm Hg, a decrease in 
right atrial pressure and cardiac output and a decrease in 
pulmonary arterial pressure due to increase in diameter or 
a relaxation of the pulmonary veins all before diuresis occurs. 
A redistribution in blood volume with much of it going to the 
limbs seems to be important at this early stage. Intact 
renal function is not necessary for this early effect. By 
15 minutes a significant increase in glomerular filtration 
rate and PAH clearance which is consistent with a rise in 
renal plasma flow occurs, and a significant diuresis begins 
which further decreases the effective plasma volume. Between 
30 and 60 minutes a further reduction in left ventricular 
filling pressure occurs this time due to the decrease in plasma 
volume due to the brisk diuresis (4-4,45) - 
Mierzwiak in 1975 (3*0 investigated the effect of large 
doses of furosemide (30 mg/kg) on the contractility of the 
heart of a vagotomized dog preparation where the blood pres¬ 
sure and heart rate were held constant. He found that after 
large doses of furosemide, no acute effects on the dog left 
ventricle (LVEDP in cm Hn0, maximum dp/dt in mm Hg/sec, stroke 
work) occurred, even after vagotomy and beta blockade. 
Therefore, any cardiovascular effects seen in man after furo¬ 
semide administration are most likely related to changes in 
effective circulating blood volume, direct affects on vascular 
beds, electrolyte alterations and reflex effects rather than 
to any direct myocardial effects(3*0. 
An interesting study by Horrobin in 197(46) showed 
that furosemide can inhibit both the potentiation and 
-17- 
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depressive responses that arterial and arteriolar smooth 
muscles have in the presence of low (50 ng/ml) and high 
(200 ng/ml) concentrations of prolactin, respectively, when 
exposed to noradrenaline and to angiotensin. Furosemide 
returned the heart rate almost to starting values whether or 
not they had been increased (with low concentration prolactin) 
or decreased (with high concentration prolactin which is in 
the range of many patients, male and female, in renal failure 
or congestive heart failure) (56). 
An important investigation closely linked to the present 
investigation was conducted by Seller in 1975 (7). Using 
therapeutic doses of digitalis, and potent diuretics in in vivo 
dog preparations, he found that the potassium sparing diuretics, 
triamterene and amiloride, reduced the digitalis-induced 
increase in myocardial loss of potassium (reduced the V-A 
difference), while the kaliuretic diuretics, furosemide and 
ethacrynic acid significantly increased the digitalis-induced 
myocardial loss of potassium (as measured by increased V-A 
difference). This finding contradicts the previous-one by 
Mierzwiak (3*0 who felt that furosemide had no direct effect 
on the myocardium although Seller did not test furosemide 
alone nor did he monitor cardiac contractility along with 
the (V-A)r. 
The finding of a cardiac effect of diuretics supports 
the premise that there may be a common enzyme system respon¬ 
sible for K+ transport across the renal tubular membrane, 




Triamterene and amiloride block renal Na+-K+ exchange due to 
a distal tubular site of action(47,48). Triamterene also 
*f* -f* -f* -j- 
stimulates both Na -K -dependent and Na -K -independent red 
blood cell rr.e(T)brame ATPase (49). In contrast, ethacrynic 
acid and possibly furosemide (potent diuretics due to their 
renal tubular sites of action (50)), have been shown to 
inhibit the digitalis-independent,Na+’K+-dependent membrane 
ATPase called "Pump II"(4l,51), which has been shown to occur 
in red blood cell membrane, as previously discussed-* It is 
possible that "PumpII" may also be present in myocardial 
membrane or be one of multiple mechanisms responsible for 
transporting potassium back into the myocardial cell, one 
which is digitalis-sensitive (Na+,K+-dependent ATPase) and 
one which is digitalis-insensitive. The latter may be 
similar to "Pump II". Thus digitalis and these kaliuretic 
diuretics may have additive blocking action regarding the 
re-entry of potassium into the myocardial cell too (7). 
Experiments combining ouabain and ethacrynic acid as 
discussed earlier resulted in a complete inhibition of 
fractional Na reabsorption and only a 46% inhibition of 
4" 4” 
Na ,K -ATPase activity. The complete inhibition of Na reab¬ 
sorption at only a partial inhibition of this ATPase is 
probably caused by additional metabolic effects of ethacrynic 
+ + 
acid. It was thus suggested that the Na ,K -ATPase is not 
the only diuretic receptor (51). Several natriuretic drugs 
have been reported to have no influence on the Na ,K -ATPase 
such as thiazides, acetazolamide, spironolactone, and xanthine 
derivatives (23). Several investigators have attempted the 
unfolding of the more intimate cellular mechanisms of furosemide 
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and other potent diuretics (18,31,51,52). Another enzyme 
possibly involved in the control of Na transport and water 
permeability is the renal adenyl cyclase(51). Under recent 
investigation is the link between furosemide and ethacrynic 
acid to cyclic 3T,5T-adenosine monophosphate (cAMP) dependent 
system. In the Kidney adenyl cyclases with different sensi¬ 
tivities to hormones exist. An ADH sensitive adenyl cyclase 
is located primarily in the renal medulla and a PTH one in 
the cortex. They both increase cAMP intracellularly in the 
medulla and cortex respectively. PTH and cAMP both inhibit 
phosphate reabsorption and increase calcium absorption(18,51). 
ADH stimulates Na transport across the tissue by increasing 
the rate of Na entry into isolated toad bladder epithelial 
cells(l8). Catecholamines can affect the kidney adenyl 
cyclase system. Beta adrenergic drugs, such as isoproterenol, 
induce an antikaliufetic effect and alpha adrenergic drugs cause 
diuresis (by inhibiting ADHaction) all via changes in cAMP(23). 
ImM furosemide and separately ImM ethacrynic acid 
inhibited adenyl cyclase in homogenates of kidney cortex and 
inner medulla, while amiloride did not. In the cortex the 
furosemide induced inhibition of adenyl cyclase can be 
reversed by 1 U PTH and 0.1 mM isoproterenol. Cortical PTH 
normalized the inhibition of adenyl cyclase by ethacrynic 
acid but the ethacrynic acid does not allow the PTH to raise 
the cAMP levels as high as without the ethacrynic acid or 
with furosemide. Ethacrynic acid is not influenced by 
isoproterenol. These data indicate that in the cortex. 
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furosemide and ethacrynic acid may act at different sites 
of the renal adenyl cyclase system. In the inner medulla 
the furosemide induced inhibition of adenyl cyclase was 
partially antagonized by ADH, but 25% inhibition remained. 
ADH did not reverse ethacrynic acid inhibition of adenyl 
cyclase at all. In addition, isoproterenol was totally inef¬ 
fective in antagonizing the inhibition of adenyl cyclase 
caused by either furosemide and/or ethacrynic acid and was 
without influence on adenyl cyclase in the absence of these 
diuretics. The different action of isoproterenol on the 
furosemide induced inhibtion of adenyl cyclases in the cortex 
and medulla suggests that the adenyl cyclases of both kidney 
zones are different. We may be looking at a mixture of 
cyclases with different sensitivities since furosemide does 
not lead to a water diuresis which might be expected if it 
is thought of as opposite to ADH in the adenyl cyclase system(51)- 
Ferguson (18) believes that these results suggest that 
ionic reabsorption in the kidney is controlled by a cAMP 
mediated system, which is inhibited by furosemide, since 
furosemide inhibits ADH and cAMP induced Na transport but 
not transport of Na in their absence in the resting condition, 
and ethacrynic acid reduces Na transport in the presence of 
ADH and in its absence, although not Na transport stimulated 
by cAMP (52). 
Biochemical studies show that ethacrynic acid reduces 
intracellular levels of cAMP, both in the resting state and 
in the presence of ADH, whereas furosemide has no effect. 




(6X10 M furosemide) displaces cAMP from specific cAMP binding 
proteins (in both rabbit muscle and toad bladder), inhibits 
the activity of a cAMP dependent protein kinase which 
phosphorylates histones in the presence of ATP, has similar 
pK’s, melting points, size and structure, almost identical 
molecular weights and at physiologic pH 7-4, they co-chromato¬ 
graph. These studies suggest that although these diuretics 
are chemically different, their similar pharmacological effects 
may be explicable by a biochemical link, possibly involving 
their effect on cAMP mechanisms (18,52). It is possible that 
the diabetogenic effects sometimes seen with the clinical 
use of furosemide may be due to its interference in the cAMP 
systems although there is no solid evidence for this (52). 
Rupp in 197^ (53) felt that the diuretic effect of 
furosemide could be predicted from serum concentrations. 
At an intravenous dose of 1 gram furosemide (in 40 minutes), 
concentrations close to 10 M were found which with 10% 
-4 
protein binding was equivalent to 10 M. This concentration 
gave extrarenal effects on Na transport in toad bladder, 
frog skin, red blood cells, smooth muscle cells and caused 
a reversible reduction in hearing. At an infusion rate of 
4 mg per minute (1 gram in 240 minutes) gave a maximum serum 
concentration below 30 ug per ml (10 M with protein binding) 
and at these concentrations no extrarenal effects were observed 
including no reduction in hearing at this concentration (53)• 
It is currently thought that potassium depletion is 
a serious hazard especially in patients in chronic heart 
failure since it seems to increase the risk of digoxin 
-22- 
- 
toxicity. This depletion is usually attributed to diuretics 
(5*0* There have been several conflicting studies as to 
whether chronic diuretic therapy actually leads to hypokalemia 
and/or to the depletion of body potassium. Since total 
extracellular fluid space contains only 3% of the total 
body content of potassium, plasma levels may not accurately 
reflect total body or intracellular potassium status (55). 
Therefore, several groups (54,56) have used the technique 
of measuring total body potassium (T.B.K.) by counting 
40 
radioactivity from the naturally occuring radionuclide K, 
the amount of which bears a constant ratio to the stable iso- 
39 
tope K which comprises the bulk of potassium. Using a 
total body monitor, the number of counts obtained is related 
to the weight of the potassium present with an accuracy by 
12-556- 
Anderson (56) in 1971 found no significant change in 
T.B.K. in hypertensive patients treated for 8 weeks with 
each of hydrochlorthiazide 50 mg twice a day and lasix 40 mg 
twice a day with an intervening placebo period for 8 weeks. 
However, Dargie (55) found that 4 months of 40 mg 
lasix per day without K supplements given to patients with 
essential hypertension led to a significant decrease in T.B.K. 
and in plasma K (3-9 to 3-6), although after 12 months of this 
therapy the T.B.K. was found to be normal again with the 
plasma K staying at the decreased value. In addition, there 
was a significant decrease in chloride at 4 months with no 
further decrease at 12 months. 
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Healy in 1970 (57) reported moderate reductions in 
total exchangeable potassium (T.E.K.) of 247 meq (which 
equals 9*8 grams K) in hypertensive patients after 15 weeks 
treatment with 40 mg lasix twice a day. This decrease in 
T.E.K. is comparable to the reduction in mean T.B.K. seen 
in Dargie's study at 4 months. But Dargie's group returned 
to baseline at one year. Dargie feels that this reduction 
and then return in T.B.K. may be due to a compensatory 
decrease in urinary K losses despite the continuation of 
other effects of furosemide, ie. the hypotensive and increase 
in uric acid effect (55), since in a non-edematous patient, 
K excretion can be as low as 15-30 mEq per day with furose¬ 
mide (56). He, therefore, concludes that there is a poor 
correlation between the slightly low serum K levels and 
T.B.K. 
Edmonds in 1975 (58) felt that lasix has a rapid 
short action, so that a single dose would not act over 
much of the 24 hours, allowing possible retention of K to 
compensate for the excess loss. He was therefore not 
surprised that Dargie's study (55) had only small decreases 
in serum K and T.B.K. He usually found that with thiazides, 
and especially in younger patients with mild to moderate 
hypertension without acid-base disturbances, that serum 
K and T.B.K. remained normal. However, he found that some 
patients did have persistent hypokalemia (less than 3.4 meq/1). 
These patients tended to be older and had more severe 
hypertension. He found that with a persistent hypokalemia. 
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a 10$ decrease in T.B.K. agreed with the two patients in 
Dargie’s study with plasma potassiums of 3.2 mEq/1. 
A possible mechanism for the decreaed potassium in 
the sicker patients may be that cardiac failure leads to 
tissue anoxia which causes the cell to be unable to accumu¬ 
late K which in turn leads to K depletion. In addition, 
in cardiac failure, secondary hyperaldosteronism leads to 
increased urinary excretion of potassium (55, 58). 
The final parameter of importance, (especially in 
the context of this study), to be presented here, is hypo¬ 
kalemia and K depletion induced by diet. 
Poole-V/ilson in 1975 (59) and Cameron in 1975 (60) 
each found, in rabbits made chronically K deficient by a 
low potassium intake for 20 days, that there was a reduced 
amount of potassium in the plasma and skeletal muscles 
(quadriceps) but no change in the amount of K in the left 
ventricle, although Cameron felt that in patients in heart 
failure, their myocardial potassium may be reduced. In 
addition, Blushke in 1976 (6l) found that in potassium- 
depleted guinea pigs (on a K deficient diet for 12 days), 
the potassium concentration in the serum and skeletal muscle 
were significantly decreased by 33$ and 11$ respectively 
with no decrease in K concentration in the heart muscle, 
and rats on a K-deficient diet for 6-8 weeks produced a 
marked reduction in the K content of the serum (from 4.9 
to 1.9 meq/1) and skeletal muscle(from 460 to 304 meq/kg) 
whereas K content of the heart muscle was only slightly, 
but not significantly, diminished (from 378 to 355 meq/kg). 
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Erdmann in 1971 (62) showed in guinea pigs that K- 
-f- -f~ 
deficiency caused an increase in activity of the Na ,K - 
activated ATPase of the heart muscle. Digitalis glycosides 
are supposed to inhibit the Na ,K -activated ATPase and 
reduce the intracellular K concentration or delay the resti¬ 
tution of the intracellular ionic concentration. Bluschke 
(6l) therefore, tested whether an inhibition of the ATPase 
by long term treatment with digitoxin might change the 
activity of the enzyme. He found in guinea pigs made hypo¬ 
kalemia with 12 days on a K deficient diet and others treated 
with 14 days of subcutaneous digitoxin (0.3 mg per kg), that 
+ + 
the activity of the Na ,K -ATPase of the heart was significantly 
enhanced by 40$ (compared to Erdmann’s 130$ increase) and 30$ 
respectively whereas this ATPase of the kidney and brain 
showed no significant change in activity compared to controls. 
During this period no relationship was found between duration 
of treatment and the size of the increase in activity. As 
“I” “i" 
the activity of the Na ,K -ATPase is dependent on the K con¬ 
centration and as cardiac glycosides are the specific inhibi¬ 
tors of this enzyme, the observed increase in activity may 
be explained by an adaptive response to an inhibition of the 
ATPase. The enzyme activity is expressed as a turnover of 
substrate per mg total protein. Therefore, an increase in 
activity may be caused by an enhanced turnover (which would 
mean a change of the specific properties of the enzyme) or 
by an increase in the amount of enzyme within total protein. 
After kinetic studies were performed, it was suggested that 
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the increase in activity may possibly be caused by an increase 




V. MATERIALS AND METHODS 
A. RADIONUCLIDE 
The radiopharmaceutical used was cyclotron produced 
ionic thallium-201 supplied as a sterile, pyrogen-free 
radiochemical in 0.9% saline at pH 5-6 in a specific activity 
of 1.0 mCi per ml. Its peak energies in tissue and blood 
samples were read in a well-type scintillation counter 
window of 60 to 100 kev. The half life of thallium-201 is 
73-5 hours. All samples were counted within 6 hours of 
injection into the animal. All counts were corrected to the 
original time of counting of the thallium doses for the day 
of the experiment. 
All calculations were normalized to a 20 kg ideal 
weight. 
Calculation 1. For blood samples: 
CPM X weight of animal in kg/20 kg _ CPM / cc-mCi 
(cc) X (mCi injected corrected back to 
injection time) 
Calculation 2. For tissue concentration of thallium-201: 
(CPM / g ) X (100) X (weight of animal in kg / 20 kg ) 
(mCi-corrected for X (standard CPM / mCi) 
time) 




B. ANIMAL PROTOCOL 
In all studies 15-25 kg mongrel dogs of both sexes 
were anesthetized with intravenous pentobarbital (25 mg/kg), 
intubated with a cuffed endotracheal tube, and ventilated on 
room air with a Harvard respirator adjusted to the dogs’ 
weight. Each dog underwent a right thoracotomy in the fourth 
or fifth interspace. The pericardium was incised and retracted. 
A polyethylene catheter was placed in the left carotid artery 
to monitor blood pressure, and in the right carotid artery 
for arterial blood collection, and in the left external 
jugular vein for injection of the furosemide, thallium and 
saline. A catheter was placed into the right external jugular 
vein and passed into the coronary sinus under visual and 
tactile observation for collection of venous blood samples. 
A foley catheter was inserted for collection of urine samples 
for measurement of urine volume, electrolytes, and for the 
timing of diureses. 
Simultaneous samples from the urine, carotid artery 
and coronary sinus were obtained twice during a control 
period. Carotid artery and coronary sinus blood samples 
were then taken every 15 seconds for 2 minutes and every 30 
seconds for the next 2 minutes after the intravenous injection 
in a bolus of 1.0 mCi thallium-201 in saline into the left 
external jugular vein. After the blood was collected, the 
animal was sacrificed, the heart removed, eight 1-2 gram 
samples of free left ventricle were used for counting tissue 
content of thallium-201. Blood samples were replaced with 
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equal volumes of normal saline. Blood pressure and EKG 
were monitored throughout the procedure. All samples were 
analyzed for sodium and potassium by flame photometry with 
an Instrumentation Laboratories flame photometer. 
The following groups of animals were studied: 
1. Control (10 animals) 
Each animal was surgically prepared and allowed to 
stabilize (blood pressure and heart rate) for at least 30 
minutes before the thallium-201 was injected. 
2. Acute lasix (9 animals) 
Each animal was surgically prepared and allowed to 
stabilize as in the control. 2mg/kg furosemide was then 
injected in a bolus intravenously via the left jugular vein. 
At its peak effective time (30 minutes post injection), the 
uptake of potassium (thallium-201) was investigated by 
injecting the bolus of 1.0 mCi of thallium-201 and collecting 
the above described carotid artery and coronary sinus blood 
samples, and then the ventricular tissue samples. 
3. Chronic lasix-normal serum potassium (7 animals) 
Each animal was injected intravenously with 1-2 mg/kg 
furosemide per day for 9 days with an average total dose of 
10.54 mg/kg while maintained on a regular diet (Purina Dog 
Chow and water). Venous blood samples were taken once a 
week and measured for serum Na and K. Each animal then 
underwent a control procedure as above. 
4. Chronic hypokalemia-no lasix (6 animals) 
Each animal was placed on special formula Purina Dog 
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Chow with only trace potassium. Blood samples were drawn 
once a week to determine serum potassium. The control 
procedure was carried out at least one week after the serum 
potassium was found to be maintained at 3-25 meq/1 or less. 
5. Chronic lasix-chronic hypokalemia (7 animals) 
Each animal was fed the trace potassium Purina Dog 
Chow and was injected intravenously with 1-2 mg/kg lasix 
per day for 3-6 weeks until blood samples determined the 
* 
serum K to be maintained at 3-25 meq/1 or less for at least 
one week. The control procedure was then carried out. 
> 
C. DIALYSIS 
In addition to being fed trace potassium food, four 
dogs in group 4 and two dogs in group 5 were dialyzed one to 
two times to speed the formation of the hypokalemic state. 
These dogs were dialyzed on a travenol machine against a 
bath with Diasol without potassium, but with physiologic 
concentrations of calcium, magnesium, sodium, chloride, 
phosphate, etc., for 30 to 45 minutes, via jugular venous 
and carotid arterial lines placed by sterile means and trans¬ 
iently for the dialysis. All dogs were allowed to stabilize 
for at least two days prior to their use in the preparation, 
with their serum potassiums measured immediately prior to 
surgery to ensure the continuance of the hypokalemic state. 
D. ANALYSIS OF HEART TISSUE POTASSIUM CONTENT 
Two to three samples of 0.5 gram pieces of left ven¬ 
tricle from 13 animals (groups 1,4 and5) were each weighed, 
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dried for three days in a 100°C oven and reweighed. Each 
sample was dissolved in concentrated nitric acid for three 
days, then heated for ten minutes on a heating plate, 
diluted up to a 10 ml total volume with water, filtered 
through glass wool and then analyzed for K and Na concentra¬ 
tion on an I.L. flame photometer. 

VI. RESULTS 
A. All Groups 
Carotid blood pressure and heart rate remained 
relatively constant throughout each study once the surgical 
preparation was completed and the animal allowed to stabilize 
for at least 30 minutes. Both the arrythmias and subsequent 
decrease in blood pressure occasionally occuring during the 
placement of the coronary sinus catheter were transient with 
a spontaneous return to the previous blood pressure, heart 
rate and EKG with the coronary sinus catheter securely in 
place. The hypokalemic dogs (groups 4 and 5) were found to 
have a higher blood pressure throughout (with means of 
225/150 and 190/1^5, respectively) than the three other 
groups with a normal serum potassium (with means of 115/89, 
120/100, and 170/145, respectively). 
B. Left Ventricular Tissue Uptake of Thallium-201 
In the control group of 10 dogs, thallium-201 left 
ventricular myocardial tissue concentration (- SEM) averaged 
0.0453 - 0.0011 % injected dose/gram, (see Table I; Figure 1,2) 
In the 9 dogs studied during the peak effect of acute 
intravenous furosemide (2mg/kg) at 30 minutes post injection. 
Group 2, myocardial thallium-201 uDtake (- SEM) was 0.0459 
- 0.0023 % injected dose which did not significantly differ 
■from control. 
Similarly, in the 7 dogs treated chronically with 
intravenous furosemide over 9 days, in the absence of hypoka- 
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lemia. Group 3, no significant alteration in thallium-201 
myocardial uptake was noted with a mean myocardial tissue 
uptake of 0.050^6 - 0.0031 % injected dose/gram. 
In the 6 dogs rendered hypokalemic with serum potassium 
going from 5-13 down to 2.95 meq/1 after 3 to 6 weeks on a 
low potassium diet with or without dialysis, Groun 4, mean 
myocardial thallium-201 concentration (- SEM) fell hy 8.Rq$ 
from control to 0.0413 - 0.0035 % injected dose/gram. This 
change in tissue thallium uptake did not significantly 
differ from the control, acute or chronic furosemide (eukale- 
i 
mic) means. See Figure 1. 
However, in the 7 dogs rendered hypokalemic with serum 
potassium going from 5.21 down to 3-098 meq/1 with chronic 
intravenous furosemide daily and a low potassium diet over 
a 3 to 6 week period,with or without dialysis, Groun 5, 
myocardial thallium-201 concentration (- SEM) fell hy 20.31 % 
to 0.0361 - 0.0022 % injected dose/gram (p<0.01 between 
this group and control, acute furosemide and chronic eukalemic 
groups.). The results obtained with the hynokalemic dogs 
were consistent within each group whether or not the dogs were 
rendered hypokalemic with diet alone or with diet and dialysis. 
C. (A-V) Differences (Carotid Artery - Coronary Sinus Blood) 
(see Table II; figure 3 ) 
Myocardial thallium-201 uptake kinetics as judged by 
A-V differences paralleled the tissue uptake with no signifi¬ 
cant differences between the control, acute furosemide and 
eukalemic chronic furosemide groups. However, the hynokalemic- 
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no furosemide group. Group 4, had the lowest (A-V) difference 
and therefore a decrease in myocardial thallium-201 uptake 
compared to all other groups from sample 4 (one and three- 
quarter minutes after the thallium injection) to the last 
sample at four minutes post thallium injection, in particular 
as compared with control (p<between 0.02 and 0.01), with 
acute furosemide (p< 0.05-0.01), with eukalemic chronic fur¬ 
osemide (p( between 0.05 and 0.01) and with chronic hypoka- 
"j 
lemic chronic furosemide (p^ 0.05) • In the chronic hypo¬ 
kalemic chronic furosemide group which statistically differed 
i 
from control, acute and eukalemic chronic furosemide, in 
myocardial tissue concentration of thallium-201, the (A-V) 
differences and therefore the thallium uptake was statistically 
different from the other groups only in scattered samples, 
(three to four minutes post thallium injection) versus control, 
(two and one half minutes to four minutes) versus acute 
furosemide, (one and one half, and three to four minutes) 
versus eukalemic chronic furosemide, and (between one to two 
minutes) versus hypokalemic-no furosemide group. 
D. Potassium Concentration in Left Ventricular Myocardium 
The three groups compared showed no significant change 
in the potassium content in the myocardium of the hypokalemic 
versus control animals. The control had a mean of 8.0873 
-0.1739 meq/wet tissue; the hypokalemic-no furosemide animals 
had a mean of 8.2339 -0.1324 meq/wet tissue and the chronic 





It was the aim of this study to see if the administra¬ 
tion of the potent diuretic, furosemide, commonly used 
clinically under both acute and chronic situations, would 
effect the uptake of an ion commonly used as a tracer in 
cardiac scanning, thallium-201. Since our results showed no 
alteration from control in thallium -201 uptake and in(A-V) 
difference in the acute and chronic normo-kalemic situation, 
we decided to pursue this investigation using chronic furose¬ 
mide under a hypokalemic environment, which is a common 
occurrence in the clinical situation. Since our results 
showed both a significant decrease in tissue (left ventricle) 
uptake of thallium-201 and a decreased (A-V) difference in 
CPM/cc/mCi with this group, we wondered if this decreased 
uptake was due to the hypokalemia alone. We therefore conducted 
a control for this situation and tested dogs made hypokalemic 
via diet alone or diet plus dialysis and no furosemide. 
These latter results were inconclusive for tissue thallium- 
201 uptake since they demonstrated a trend toward values 
lower than the control, acute and chronic furosemide-normo- 
kalemic dogs, and higher than the one group that differed 
significantly from control, the hypokalemic chronic furosemide 
group. Group 5. Therefore this hypokalemic-no furosemide 
group , Group 4, approached but did not achieve statistical 
significance from any other group. More studies, currently 
under way, will be needed to resolve whether this group with 
hypokalemia alone, will stand as a group by itself, will 
merge with the control group, or will merge with the one 
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significantly different group with decreased thallium-201 
uptake, the hypokalemic, chronic furosemide group. If the 
last possibility comes about, it could be interpreted as 
meaning that it was the hypokalemic environment and not the 
furosemide which most likely caused the decrease in myocar¬ 
dial thallium-201 uptake. If it trends toward the control 
group, it would seem likely that a possible interpretation 
would be that both a hypokalemic environment along with the 
chronic administration of furosemide is needed to effect the 
cationic balance and enzyme systems enough to result in a 
decreased uptake of thallium-201 by the heart. If, with 
more studies, it stands as a group by itself, and becomes 
significantly different from and in between both the control 
and hypokalemic,chronic furosemide groups, it would lend itself 
to the interpretation that several factors, each contributing 
to the whole, influence thallium-201 uptake by the heart, and 
the more of these factors (hypokalemia, chronic furosemide, 
etc.) are on board in the environment, the less thallium-201 
uptake will occur. 
Of considerable interest are the (A-V) difference 
results of the various, with the hypokalemic only groun (GrouD 4) 
showing a significantly smaller (A-V) difference, indicating 
the smallest uptake of thallium-201, than every other group 
including the hypokalemic, chronic furosemide group (Group 5) 
although only in scattereu samples. This would indicate that 
these future studies will probably result in the hypokalemic 
group (Group 4) either standing on its own or merging with 






Although the biochemical mechanisms governing 
thallium-201 uptake, along with how various environmental 
factors may alter this uptake, have not as yet been resolved, 
some interpretation of how studies presented earlier in this 
paper, may be relevant to the results of this study will 
be attempted. 
It has been shown by numerous investigators that an 
environment with low external serum potassium (hypokalemia) 
results in a decreased uptake of Na+ and K+ by kidney tubules 
and red blood cells (32,39,40,41,42). Since thallium-201 
has been shown to act as potassium in vivo (1,2,8,9) it would 
not be unexpected to get a decrease in tissue uptake of 
thallium-201 in a hypokalemic environment. In addition, 
studies have shown furosemide to inhibit cation co-transport 
and block uptake of Na+ and K+ in various tissues (red blood 
cells, renal tubules, salivary duct epithelium)(7,31,32,3Q,40). 
To further support the idea that furosemide directly 
inhibits potassium uptake by the heart. Seller in 1975 (7) 
found that furosemide significantly increased the digitalis 
induced myocardial loss of potassium (as measured by increased 
coronary sinus-femoral artery potassium difference). 
Thus furosemide may act synergistically with the 
hypokalemia and lead to a decrease in thallium-201 uptake 
by the heart. 
If furosemide inhibits myocardial potassium uptake as 
the studies seem to show, one may wonder why the acute and 
chronic administration of furosemide without hypokalemia 
did not lead to a decreased tissue uptake of thallium-201 or 
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a decrease in (A-V) difference. One may speculate that a 
higher serum concentration of furosemide might be needed to 
see an effect and/or that the normal to high serum potassium 
of 5.1 in the non-hypokalemic animals may have overridden 
the effect that might be seen with furosemide alone. The 
chronic furosemide together with low serum potassium would, 
leave no opposing force to the furosemide?s inhibition to 
potassium, or in this case, thallium-201 uptake. 
It is possible that with the cardiac tissue retaining 
its potassium content, while the serum and skeletal muscles 
show concomitant reductions in potassium, when made chronically 
potassium deficient via diet, as shown by Poole-Wilson in 1Q75 
(59), and Cameron in 1975 (6l), and this study, that the 
potassium deficient serum and skeletal muscles may act as a 
sink for the bolus of thallium-201 injected, thus leading to 
decreased myocardial uptake of this ion, with none of the 
projected effects on enzyme systems actually occurring as 
speculated above. 
Since the localization of an infarct with thallium-201 
imaging agent is dependent on the lack of perfusion to the 
infarcted area with a subsequent lack of thallium—201 uptake 
in that area and thereby the visualization of a "cold spot", 
the occurrence of a decreased uptake of thallium-201 into 
normal myocardium under various conditions (hypokalemia and 
furosemide) would obscure the differences from the abnormal 
zones under these conditions. 
In addition to the finding that acutely reduced serum 
potassium leads to reduced potassium uptake by kidney tubules 
and erythrocytes, Erdman in 1971 (62) and Bluschke in 1976(61) 
-39- 
" 
found that 12 days of hypokalemia from diet significantly 
enhanced the activity of cardiac Na+,K+-ATPase which would 
presumably lead to an increased myocardial potassium uptake 
whereas this ATPase of the kidney and brain showed no signi¬ 
ficant change in activity from controls. The same result 
was found with 14 days of subcutaneous digoxin (0.3 mg/kg), 
an inhibitor of this ATPase. As the activity of the Na+,K+- 
ATPase is dependent on the potassium concentration and as 
cardiac glycosides are the specific inhibitors of this 
enzyme, the observed increase in activity may be explained 
by an adaptive reponse to the inhibition of the ATPase (6l). 
This increased ATPase activity would presumably return the 
myocardial potassium uptake toward normal in the face of its 
inhibitors (hypokalemia and/or digoxin). 
To relate these findings to the present study, it is 
possible that the hypokalemic alone group, Grouo 4, had 
increased cardiac Na+,K+-ATPase activity due to the chronic 
hypokalemia which in turn prevented the expected decrease 
in thallium-201 uptake (also due to the decrease in external 
serum potassium). It is possible that this group's intermediate 
mean value for tissue uptake of thallium-201 was due to 
these opposing factors. In the chronic hypokalemic chronic 
furosemide group. Group 5, this possible increase in ATPase 
activity may have been inhibited by the action of the furose¬ 
mide leading to the significant reduction in myocardial uptake 
of thallium-201. If this was so though, one must question 
why the chronic furosemide alone did not result in an even 
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greater reduction of uptake. One might also speculate as 
to whether furosemide (itself an ATPase inhibitor) might 
also lead to an increase in the activity of this ATPase if 
given chronically, as did the digoxin. 
In the view of this author and Seller (7), it is 
more probable that the furosemide and hypokalemia may more 
directly effect the sites where the potassium and thallium- 
201 act on the myocardium than the above study on the 
induction of the Na+,K+-ATPase. 
From this present study, it is possible to make 
i 
several inferences on how the information gained may be 
useful in the clinical situation when quantifying thallium- 
201 scans or looking for relative differences between scans. 
Let us suppose that a patient is admitted with a diagnosis 
of acute myocardial infarction or is to have an myocardial 
infarction ruled out, and it is decided that a thallium-201 
scan would be an appropriate tool in his management, it 
would be most important in the quantitative interpretation 
of that and subsequent scans to know if he is currently 
hypokalemic and/or taking medications such as furodemide, on 
a long term basis or even acutely. From this study, we 
would expect his scanning results to be the same as control 
as long as the patient has a normal serum potassium,no 
matter what his history of taking furosemide. If he has been 
chronically on furosemide and is hypokalemic alone, then the 
uptake of the myocardial thallium-201 will be influenced. 
If normal myocardial tissue is influenced by these various 
environments to have a decrease in thallium-201 uptake then 
- 
the contrast between normal and abnormal regions will be de¬ 
creased resulting in an inability to detect a lesion or the 




























Decrease in thallium-201 Uptake in Canine Free 
Left Ventricle under control, acute and chronic 
furosemide and under normal and hypokalemic 
conditions. The numbers in the lower part of 
each column represents the number of experiments 
of each kind. The number in the parenthesis is 
the group number. 
p < 0. 01 
(1) = control 
(2) = acute furosemide 
(3) = chronic furosemide 
(4) = hypokalemia alone 
(5) = hypokalemia and furosemide 
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